lifestyle.harcourthealth.com

Author: Capwell Communications

JASMINE Trial Demonstrates Prolacta’s Human Milk-Based Fortifiers Deliver Superior Growth in Premature Infants While Maintaining Japan’s Renowned Low NEC Rate

April 30, 2026
Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company’s Integrated Sacral Neuromodulation System for Urinary Urge Incontinence

March 5, 2026
A World-First in Neonatal Care: Japan Approves Prolacta Bioscience’s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

February 19, 2026
A World-First in Neonatal Care: Japan Approves Prolacta Bioscience’s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

February 18, 2026
Neuspera Medical Announces Milestone Case of Traditional Sacral Neuromodulation (SNM) System Removed and Replaced With the Company’s Integrated SNM System for Urinary Urge Incontinence

February 11, 2026
Most Comprehensive Meta-Analysis to Date Finds an Exclusive Human Milk Diet Is Associated With Up to 49% Lower Risk of Necrotizing Enterocolitis in Premature Infants

November 17, 2025